@targetedonc.bsky.social
📤 158
đź“Ą 121
đź“ť 102
The FDA designates iza-bren as a breakthrough therapy for advanced EGFR-mutant NSCLC, promising improved outcomes for patients with limited options. Read the full story here →
www.targetedonc.com/view/izalont...
loading . . .
Izalontamab Brengitecan Earns FDA Breakthrough Designation in EGFR+ NSCLC
The FDA designates iza-bren as a breakthrough therapy for advanced EGFR-mutant NSCLC, promising improved outcomes for patients with limited options.
https://hubs.li/Q03D9XqM0
10 months ago
0
1
0
New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive bladder cancer patients ineligible for cisplatin. Read more→
www.targetedonc.com/view/neoadju...
loading . . .
Neoadjuvant Pembrolizumab and Enfortumab Vedotin Improve Outcomes in MIBC
New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive bladder cancer patients ineligible for cisplatin.
https://www.targetedonc.com/view/neoadjuvant-pembrolizumab-and-enfortumab-vedotin-improve-outcomes-in-mibc
10 months ago
0
0
0
The FDA has granted accelerated approval to
#zongertinib
in HER2+
#NSCLC
. Read about the breaking regulatory decision here →
www.targetedonc.com/view/fda-gra...
loading . . .
FDA Grants Accelerated Approval to Zongertinib in HER2 NSCLC
Zongertinib gains FDA approval for advanced NSCLC with HER2 mutations, showcasing promising efficacy and safety in clinical trials.
https://www.targetedonc.com/view/fda-grants-accelerated-approval-to-zongertinib-in-her2-nsclc
10 months ago
0
0
0
BREAKING NEWS: The FDA granted accelerated approval to dordaviprone (Modeyso) for adult and pediatric patients with diffuse midline glioma, marking a major step forward in this patient population. Read more about the approval here →
www.targetedonc.com/view/dordavi...
loading . . .
Dordaviprone Receives Accelerated FDA Approval for Diffuse Midline Glioma
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
https://www.targetedonc.com/view/dordaviprone-receives-accelerated-fda-approval-for-diffuse-midline-glioma
10 months ago
0
0
0
July marked a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment options for various cancers. Read up on all of the FDA happenings in our monthly recap:
www.targetedonc.com/view/july-20...
loading . . .
July's Oncology Approvals: A Landmark Month for Cancer Treatment Advancements
July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment options for various cancers.
https://hubs.li/Q03zYrt90
10 months ago
0
0
0
Game-changer in CLL/SLL? Pirtobrutinib's Phase 3 data reveals it's matching and potentially outperforming ibrutinib in ORR. Its noncovalent mechanism is key for overcoming resistance. A promising development for our clinical community.
www.targetedonc.com/view/optimiz...
loading . . .
Optimizing CLL/SLL Therapy: Pirtobrutinib Matches Ibrutinib in Phase 3
Pirtobrutinib shows promising results in treating CLL, outperforming ibrutinib in a pivotal phase 3 trial, paving the way for broader applications.
https://www.targetedonc.com/view/optimizing-cll-sll-therapy-pirtobrutinib-matches-ibrutinib-in-phase-3
10 months ago
0
0
0
Ateganosine has received FDA Fast Track designation for advanced NSCLC progressing after ICI therapy. This novel telomere-targeting agent is showing promising early clinical data. Explore the full article for insights into this critical development.
www.targetedonc.com/view/ategano...
loading . . .
Ateganosine Receives FDA Fast Track Designation for NSCLC
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
https://www.targetedonc.com/view/ateganosine-receives-fda-fast-track-designation-for-nsclc
10 months ago
0
0
0
Durvalumab just received FDA Priority Review & Breakthrough Therapy for resectable early-stage gastric/GEJ cancers. This could be the first perioperative immunotherapy in this setting, addressing a high unmet need. Read the full story here:
www.targetedonc.com/view/durvalu...
loading . . .
Durvalumab Earns FDA Priority Review for Early-Stage Gastric Cancer
Durvalumab's breakthrough therapy designation offers hope for improved outcomes in early-stage gastric and GEJ cancers, potentially transforming treatment strategies.
https://www.targetedonc.com/view/durvalumab-earns-fda-priority-review-for-early-stage-gastric-cancer
10 months ago
0
0
0
FDA grants priority review to tabelecleucel for relapsed/refractory EBV+ PTLD, a critical step towards the first approved therapy for this severe posttransplant malignancy. PDUFA date Jan 10, 2026.
#EBVPTLD
#CellTherapy
#FDA
#Oncology
www.targetedonc.com/view/fda-gra...
loading . . .
FDA Grants Priority Review to Tab-cel for EBV+ PTLD After Prior Therapies
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
https://www.targetedonc.com/view/fda-grants-priority-review-to-tab-cel-for-ebv-ptld-after-prior-therapies
10 months ago
0
0
0
The EU approved belantamab mafodotin (Blenrep) combinations in R/R multiple myeloma, enhancing treatment options for relapsed multiple myeloma patients with promising efficacy and safety profiles. Read the full story:
www.targetedonc.com/view/eu-appr...
loading . . .
EU Approves Belantamab Mafodotin Combinations for Relapsed/Refractory Myeloma
The EU approves belantamab mafodotin combinations, enhancing treatment options for relapsed multiple myeloma patients with promising efficacy and safety profiles.
https://www.targetedonc.com/view/eu-approves-belantamab-mafodotin-combinations-for-relapsed-refractory-myeloma
10 months ago
1
1
0
Luspatercept (Reblozyl) phase 3 INDEPENDENCE trial missed its primary endpoint for RBC transfusion independence but showed promising secondary benefits, like reduced transfusion burden & increased hemoglobin.
hubs.li/Q03ycfyx0
#Myelofibrosis
#Anemia
#ClinicalTrials
loading . . .
Luspatercept Misses Primary End Point, Shows Clinically Meaningful Secondary Benefits
Luspatercept shows promise in improving anemia in myelofibrosis patients, despite not meeting primary trial endpoints, highlighting ongoing treatment challenges.
https://hubs.li/Q03ycfyx0
11 months ago
0
0
0
The FDA has issued a CRL for RP1 in advanced melanoma, primarily due to concerns about the interpretability of the IGNYTE trial's results and questions on the confirmatory trial design. This emphasizes the strict regulatory requirements for new therapies.
www.targetedonc.com/view/fda-iss...
loading . . .
FDA Issues CRL for RP1 in Advanced Melanoma
Replimune faces FDA hurdles for RP1, an innovative melanoma treatment, as it seeks a path forward after receiving a complete response letter.
https://www.targetedonc.com/view/fda-issues-crl-for-rp1-in-advanced-melanoma
11 months ago
0
0
0
Final OS data from FLAURA2 confirm osimertinib + platinum-based chemo significantly extends survival in 1L EGFRm NSCLC. A potential new standard of care. Read more:
hubs.li/Q03y1gxQ0
#LungCancer
#EGFRm
#NSCLC
#Oncology
#ClinicalTrials
loading . . .
Osimertinib Plus Chemotherapy Significantly Extends Survival in Advanced EGFRm NSCLC
Osimertinib plus chemotherapy significantly improves overall survival in EGFRm NSCLC, signaling a new standard of care.
https://hubs.li/Q03y1gxQ0
11 months ago
0
0
0
FDA issues CRL for glofitamab + GemOx in 2L R/R DLBCL, citing limited US patient enrollment in STARGLO study. Glofitamab retains accelerated approval as monotherapy in later lines. Important regulatory update for clinicians.
#Lymphoma
#DLBCL
#OncTwitter
#FDA
www.targetedonc.com/view/fda-iss...
loading . . .
FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy
FDA issues a complete response letter for glofitamab's second-line DLBCL indication, highlighting ongoing scrutiny in oncology therapy approvals.
https://www.targetedonc.com/view/fda-issues-complete-response-letter-for-glofitamab-in-r-r-dlbcl-combination-therapy
11 months ago
1
0
0
reposted by
SWOG Cancer Research Network
11 months ago
Thank you,
@targetedonc.bsky.social
, for reporting on this subset analysis from the
@swog.org
S1826 trial, recently publ in JCO: Nivolumab Plus AVD Outperforms Brentuximab Vedotin-Based Regimen in Older Patients With Classic Hodgkin Lymphoma
targetedonc.com/view/nivolum...
loading . . .
Nivolumab Plus AVD Outperforms Brentuximab Vedotin-Based Regimen in Older Patients With Classic Hodgkin Lymphoma
A recent trial reveals that nivolumab combined with chemotherapy significantly improves survival rates in older patients with advanced Hodgkin lymphoma.
https://targetedonc.com/view/nivolumab-plus-avd-outperforms-brentuximab-vedotin-based-regimen-in-older-patients-with-classic-hodgkin-lymphoma
0
1
1
BREAKING: The
#FDA
granted accelerated approval to datopotamab deruxtecan (Datroway) for adult patients with locally advanced or metastatic EGFR-mutated
#NSCLC
who have previously received systemic therapies, including EGFR-targeted treatments.
www.targetedonc.com/view/fda-gra...
loading . . .
FDA Grants Accelerated Approval to Dato-DXd in Previously Treated EGFR+ NSCLC
FDA accelerates approval of datopotamab deruxtecan for advanced EGFR-mutated NSCLC, offering new hope for previously treated patients.
https://www.targetedonc.com/view/fda-grants-accelerated-approval-to-dato-dxd-in-previously-treated-egfr-nsclc?utm_content=336320296&utm_medium=social&utm_source=twitter&hss_channel=tw-726304448
12 months ago
0
0
0
#ASCO25
Recap: Immunotherapy takes center stage! Dr. David Spigel shares the key highlights. ▶️ Watch now!
#CancerTreatment
#SarahCannon
loading . . .
about 1 year ago
1
0
0
Follow along for real-time updates from
#ASCO25
and insights from the ground floor of the world’s leading oncology conference!
www.targetedonc.com/conference/a...
#OncologyInnovation
#MedicalOncology
#CancerResearch
#PrecisionMedicine
about 1 year ago
0
0
0
Anlotinib showed noninferior PFS vs bevacizumab when either agent was combined with first-line CapeOX chemotherapy in Chinese patients with RAS/BRAF wild-type, unresectable
#mCRC
, meeting the primary end point of the phase 3 ANCHOR trial.
#crcsm
#ASCO25
www.targetedonc.com/view/anlotin...
loading . . .
Anlotinib Noninferior to Bevacizumab in Frontline RAS/BRAF Wild-Type mCRC
Anlotinib plus chemotherapy has emerged as a first-line alternative to bevacizumab/chemotherapy in RAS/BRAF wild-type metastatic colorectal cancer.
https://www.targetedonc.com/view/anlotinib-noninferior-to-bevacizumab-in-frontline-ras-braf-wild-type-mcrc?utm_content=334384481&utm_medium=social&utm_source=twitter&hss_channel=tw-726304448
about 1 year ago
0
1
0
Big news from the May 21
#ASCO25
press briefing: 🔹 GLP-1s show cancer risk reduction 🔹 AI boosts HER2-low scoring accuracy 🔹 Inavolisib triplet extends survival in PIK3CA-mutant breast cancer 🔹 Lurbinectedin combo shows OS/PFS gains in SCLC
www.targetedonc.com/view/asco-20...
loading . . .
ASCO 2025 Briefing: Advances in Breast, Lung, and Obesity-Linked Cancers
The ASCO 2025 press briefing showcased early highlights in cancer therapy. Here’s what you need to know.
https://www.targetedonc.com/view/asco-2025-briefing-advances-in-breast-lung-and-obesity-linked-cancers
about 1 year ago
0
1
0
reposted by
Ruesch Center
about 1 year ago
John L. Marshall, MD, (
@marshalj23.bsky.social
) discusses unmet needs in the targeted therapy space and the importance of optimizing dosing in colorectal cancer with
@targetedonc.bsky.social
.
www.targetedonc.com/view/unmet-n...
loading . . .
Unmet Needs and Therapy Modifications Relevant in the CRC Landscape
John L. Marshall, MD, discusses unmet needs in the targeted therapy space and the importance of optimizing dosing in colorectal cancer.
https://www.targetedonc.com/view/unmet-needs-and-therapy-modifications-relevant-in-the-crc-landscape
0
2
1
Today is
#ClinicalTrialsDay
! Here, Manmeet Ahluwalia, MD, MBA, FASCO, highlights genomic testing as a crucial area of current research with immediate implications for patients with brain cancer.
www.targetedonc.com/view/clinica...
loading . . .
Clinical Trial Awareness Day: Progress in Brain Cancer Research
Manmeet Ahluwalia, MD, MBA, FASCO, highlights genomic testing as a crucial area of current research with immediate implications for patients with brain cancer.
https://www.targetedonc.com/view/clinical-trial-awareness-day-progress-in-brain-cancer-research
about 1 year ago
0
0
0
BREAKING: The
#FDA
has approved retifanlimab-dlwr for the treatment of advanced squamous cell carcinoma of the anal canal as a monotherapy and in combination with chemotherapy.
#SCAC
www.targetedonc.com/view/fda-app...
loading . . .
FDA Approves Retifanlimab, First Frontline Treatment for Advanced SCAC
With significant survival improvements seen, the FDA has granted approval to retifanlimab for the first-line treatment of advanced anal cancer.
https://www.targetedonc.com/view/fda-approves-retifanlimab-first-frontline-treatment-for-advanced-scac?utm_content=332919974&utm_medium=social&utm_source=twitter&hss_channel=tw-726304448
about 1 year ago
0
0
0
The Targeted Pulse: The
#FDA
has cleared investigational new drug applications and handed out fast track designations. Plus, data shows promise for novel therapies in hard-to-treat cancers.
www.targetedonc.com/view/targete...
loading . . .
The Targeted Pulse: New Therapies for Melanoma, Myeloma, and More
The FDA has cleared investigational new drug applications and handed out fast track designations. Plus, data shows promise for novel therapies in hard-to-treat cancers.
https://www.targetedonc.com/view/targeted-pulse-may-11?utm_content=332584322&utm_medium=social&utm_source=twitter&hss_channel=tw-726304448
about 1 year ago
0
0
0
The
#FDA
has accepted the biologics license application resubmission for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.
www.targetedonc.com/view/fda-acc...
loading . . .
FDA Accepts Narsoplimab BLA Resubmission for Transplant-Associated TMA
The resubmitted biologics license application for narsoplimab in transplant-associated thrombotic microangiopathy has been accepted by the FDA.
https://www.targetedonc.com/view/fda-accepts-narsoplimab-bla-resubmission-for-transplant-associated-tma
about 1 year ago
0
0
0
The
#FDA
has issued a refusal to file letter for the supplemental biologics license application seeking approval of nogapendekin alfa inbakicept in combination with Bacillus Calmette-Guérin.
#blcsm
www.targetedonc.com/view/fda-iss...
www.targetedonc.com/view/fda-iss...
loading . . .
FDA Issues Refusal to File for Nogapendekin Alfa Plus BCG in Papillary NMIBC
The FDA issued an RTF for sBLA of nogapendekin alfa plus BCG for BCG-unresponsive NMIBC papillary disease, following prior positive feedback.
https://www.targetedonc.com/view/fda-issues-refusal-to-file-for-nogapendekin-alfa-plus-bcg-in-papillary-nmibc
about 1 year ago
0
0
0
#AUA25
has kicked off, and for oncologists specializing in bladder cancer, several key presentations are offering compelling insights into potential shifts in treatment paradigms. Learn more in this video!
@mayocliniccancer.bsky.social
#blcsm
www.targetedonc.com/view/bladder...
loading . . .
Bladder Cancer Takes Center Stage With Breakthrough Advancements at AUA 2025
Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.
https://www.targetedonc.com/view/bladder-cancer-takes-center-stage-with-breakthrough-advancements-at-aua-2025?utm_content=331302007&utm_medium=social&utm_source=twitter&hss_channel=tw-726304448
about 1 year ago
0
0
0
Listening in on Dr. Yijun Shen’s presentation at
#AUA25
regarding DV + BCG in
#NMIBC🔊Stay
tuned for more on the story at
targetedonc.com/conference/aua
about 1 year ago
0
0
0
Dr. Jacob stopped by to Targeted Oncology at
#AUA25
to discuss cohort 2 of the SunRISe-1 trial of TAR-200 in
#NMIBC
!
@upstatemedical.bsky.social
Listen to his great insights here:
www.targetedonc.com/view/tar-200...
loading . . .
TAR-200 Shows Durable Response in BCG-Unresponsive NMIBC: SunRISe-1 Cohort 2
Joseph Jacob, MD, discusses data from the phase 2b SunRISe-1 study, cohort 2, evaluating TAR-200 in BCG-unresponsive high-risk NMIBC with carcinoma in situ.
https://www.targetedonc.com/view/tar-200-shows-durable-response-in-bcg-unresponsive-nmibc-sunrise-1-cohort-2
about 1 year ago
0
0
0
Urine Luck! Targeted Oncology is live from
#AUA25
, bringing you the latest breakthroughs and insights straight from the meeting floor. Stay tuned for exclusive updates!
about 1 year ago
0
0
0
#FDA
Oks Penpulimab for First-Line Non-Keratinizing Nasopharyngeal Carcinoma
www.targetedonc.com/view/fda-oks...
loading . . .
FDA Oks Penpulimab for First-Line Non-Keratinizing Nasopharyngeal Carcinoma
The FDA has approved penpulimab with chemotherapy for first-line recurrent/metastatic non-keratinizing nasopharyngeal carcinoma and alone after prior treatment.
https://www.targetedonc.com/view/fda-oks-penpulimab-for-first-line-non-keratinizing-nasopharyngeal-carcinoma?utm_content=331124663&utm_medium=social&utm_source=facebook&hss_channel=fbp-151263018348271
about 1 year ago
0
1
0
đź“Ť Headed to
#AUA25
in Las Vegas? Urologic oncologists, don’t miss our exclusive preview of the most practice-changing data, breakthrough therapies, and must-see sessions in GU oncology. 🔍💡 Sign up to learn more!
#gucsm
www.targetedonc.com/view/aua-202...
loading . . .
AUA 2025: A Sneak Peek for Community Oncologists/Urologists
At AUA 2025, experts will present on novel bladder cancer therapies, advanced renal cell carcinoma comparisons, frailty in prostate cancer, and more.
https://www.targetedonc.com/view/aua-2025-a-sneak-peek-for-community-oncologists-urologists
about 1 year ago
0
0
0
The week marked several
#FDA
approvals for drugs and devices, plus data continues to show tarlatamab’s benefit in small cell lung cancer.
#SCLC
www.targetedonc.com/view/targete...
loading . . .
The Targeted Pulse: FDA Approvals in HCC and CRC, Promise for SCLC, and More
The week marked several FDA approvals for drugs and devices, plus data continues to show tarlatamab’s benefit in small cell lung cancer.
https://www.targetedonc.com/view/targeted-pulse-april-20?utm_content=330856247&utm_medium=social&utm_source=twitter&hss_channel=tw-726304448
about 1 year ago
0
0
0
The
#FDA
has granted breakthrough device designation to the DAMO PANDA, an artificial intelligence-powered model used to detect pancreatic cancer.
#pancsm
www.targetedonc.com/view/ai-tool...
loading . . .
AI Tool Earns FDA Breakthrough Device Designation in Pancreatic Cancer
The DAMO PANDA can accurately detect pancreatic cancer lesions, and FDA breakthrough therapy designation aims to accelerate its development and approval.
https://www.targetedonc.com/view/ai-tool-earns-fda-breakthrough-device-designation-in-pancreatic-cancer
about 1 year ago
0
0
0
In a phase 2 trial, a potential survival benefit was seen with the combination of Bria-IMT and immune checkpoint inhibition in patients with heavily pretreated metastatic HR+ breast cancer.
#bcsm
www.targetedonc.com/view/bria-im...
loading . . .
Bria-IMT Plus Retifanlimab Shows Promising Survival in HR+ Breast Cancer
Phase 2 data suggest a survival benefit with Bria-IMT and retifanlimab in heavily pretreated HR-positive metastatic breast cancer, outperforming historical controls.
https://www.targetedonc.com/view/bria-imt-plus-retifanlimab-shows-promising-survival-in-hr-breast-cancer
about 1 year ago
0
0
0
Iltamiocel, an investigational cell therapy, has been granted RMAT designation by the
#FDA
in patients with oropharyngeal dysphagia, a common complication following treatment for head and neck cancer.
#hancsm
www.targetedonc.com/view/fda-gra...
loading . . .
FDA Grants Novel Therapy RMAT Designation for Dysphagia Following Head and Neck Cancer Treatment
The FDA granted regenerative medicine advanced therapy designation to iltamciocel for patients with oropharyngeal dysphagia following head and neck cancer treatment.
https://www.targetedonc.com/view/fda-grants-rmat-designation-to-novel-therapy-for-dysphagia-following-head-and-neck-cancer-treatment
about 1 year ago
0
0
0
ImmunityBio, Inc. announced multiple regulatory submissions to the
#FDA
, including expanding the utility of nogapendekin alfa in BCG-unresponsive
#NMIBC
with papillary disease and for the treatment of lymphopenia in patients with cancer.
#blcsm
www.targetedonc.com/view/fda-to-...
loading . . .
FDA to Review Nogapendekin Alfa in Bladder Cancer and Lymphopenia
A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus Calmette-Guérin in papillary non-muscle invasive bladder cancer.
https://www.targetedonc.com/view/fda-to-review-nogapendekin-alfa-in-bladder-cancer-and-lymphopenia?utm_content=330447757&utm_medium=social&utm_source=twitter&hss_channel=tw-726304448
about 1 year ago
0
0
0
Following a successful Type D meeting with the
#FDA
, IDEAYA Biosciences announced a phase 3 registrational trial design to evaluate the safety and efficacy of darovasertib as neoadjuvant therapy for the treatment of patients with primary uveal
#melanoma
.
www.targetedonc.com/view/fda-bac...
loading . . .
FDA Backs Darovasertib Phase 3 Trial Design in Uveal Melanoma
Following a recent Type D meeting with the FDA, a phase 3 clinical trial design for darovasertib in primary uveal melanoma has been announced.
https://www.targetedonc.com/view/fda-backs-darovasertib-phase-3-trial-design-in-uveal-melanoma?utm_content=330277667&utm_medium=social&utm_source=twitter&hss_channel=tw-726304448
about 1 year ago
0
0
0
BREAKING: The
#FDA
approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the first-line treatment of patients with unresectable hepatocellular carcinoma.
#HCC
www.targetedonc.com/view/fda-app...
loading . . .
FDA Approves Nivolumab/Ipilimumab in First-Line Hepatocellular Cancer
Findings from the CheckMate 9DW trial support the FDA approval of nivolumab and ipilimumab in unresectable hepatocellular carcinoma
https://www.targetedonc.com/view/fda-approves-nivolumab-ipilimumab-in-first-line-hepatocellular-cancer
about 1 year ago
0
0
0
WATCH: Enriqueta Felip, MD, PhD, discusses the phase 3 3475A-D77 study of subcutaneous pembrolizumab plus chemotherapy in metastatic
#NSCLC
.
#lcsm
www.targetedonc.com/view/phase-3...
loading . . .
Phase 3 Trial Evaluates SC Pembrolizumab vs IV in NSCLC
Enriqueta Felip, MD, PhD, discusses the phase 3 3475A-D77 study of subcutaneous pembrolizumab plus chemotherapy in metastatic non–small cell lung cancer.
https://www.targetedonc.com/view/phase-3-trial-evaluates-sc-pembrolizumab-vs-iv-in-nsclc?utm_content=329603092&utm_medium=social&utm_source=twitter&hss_channel=tw-726304448
about 1 year ago
0
0
0
Treatment with vepdegestrant extended PFS vs fulvestrant in patients with ESR1m+, ER+/HER2– breast cancer who progressed on CDK 4/6 inhibitors and endocrine therapy.
#bcsm
www.targetedonc.com/view/vepdege...
loading . . .
Vepdegestrant Improves PFS in ESR1-Mutated Breast Cancer
Vepdegestrant extended PFS vs fulvestrant in patients with ESR1m+, ER+/HER2– breast cancer who progressed on CDK 4/6 inhibitors and endocrine therapy.
https://www.targetedonc.com/view/vepdegestrant-improves-pfs-in-esr1-mutated-breast-cancer?utm_content=329476165&utm_medium=social&utm_source=twitter&hss_channel=tw-726304448
about 1 year ago
0
1
0
The
#FDA
has granted breakthrough device designation to Paige PanCancer Detect, an AI-assisted diagnostic application capable of identifying both common cancers and rare variants across diverse anatomical sites.
www.targetedonc.com/view/paige-p...
loading . . .
Paige PanCancer Detect Earns FDA Designation for Multi-Tissue Cancer Detection
Paige PanCancer Detect has gained FDA breakthrough device designation, a first for AI identifying diverse cancers across tissues.
https://www.targetedonc.com/view/paige-pancancer-detect-earns-fda-designation-for-multi-tissue-cancer-detection
about 1 year ago
0
0
0
reposted by
Ishwaria Subbiah MD, MS, FASCO
about 1 year ago
Insightful piece from Janet Abrahm, MD on the hidden role of unprocessed
#grief
in
#compassionfatigue
and the alarming 59%
#burnout
rate among
#oncologists
. đź”—
www.targetedonc.com/view/grief-s...
via
@targetedonc.bsky.social
#wellbeing
0
4
1
WATCH: Regina Barragan-Carrillo, MD, evaluates the current state of the global availability of clinical trials for patients with
#RCC
.
#kcsm
|
@cityofhope.bsky.social
www.targetedonc.com/view/study-r...
loading . . .
Study Reveals Stark Disparities in RCC Clinical Trial Access Worldwide
Regina Barragan-Carrillo, MD, evaluates the current state of the global availability of clinical trials for patients with renal cell carcinoma.
https://www.targetedonc.com/view/study-reveals-stark-disparities-in-rcc-clinical-trial-access-worldwide?utm_content=329011211&utm_medium=social&utm_source=twitter&hss_channel=tw-726304448
about 1 year ago
0
0
0
In this interview, Jennifer Chan, MD, MPH, discussed the recent
#FDA
approval of
#cabozantinib
in pancreatic and extrapancreatic neuroendocrine tumors.
@danafarber.bsky.social
www.targetedonc.com/view/behind-...
about 1 year ago
0
0
0
Take a look back on all the
#FDA
happenings from the month of March 2025:
www.targetedonc.com/view/fda-onc...
about 1 year ago
0
0
0
BREAKING: The
#FDA
approved durvalumab (Imfinzi) plus chemotherapy followed by single-agent durvalumab for the treatment of patients with muscle-invasive bladder cancer after radical cystectomy.
#blcsm
www.targetedonc.com/view/fda-gra...
about 1 year ago
0
0
0
The presence of mKRAS ctDNA in plasma and peritoneal fluid was associated with increased risk of metastatic progression and worse overall survival in patients with localized pancreatic ductal adenocarcinoma.
#PDAC
#pancsm
www.targetedonc.com/view/mkras-c...
loading . . .
mKRAS ctDNA Emerges as Predictor of Metastasis, Survival in PDAC
Mutant KRAS in ctDNA in patients with localized pancreatic cancer was shown to be a biomarker for metastatic progression and overall survival.
https://www.targetedonc.com/view/mkras-ctdna-emerges-as-predictor-of-metastasis-survival-in-pdac?utm_content=328368013&utm_medium=social&utm_source=twitter&hss_channel=tw-726304448
about 1 year ago
0
0
0
WATCH: Nicolas Girard, MD, PhD, discusses the final overall survival results from the MARIPOSA trial of amivantamab plus lazertinib in EGFR-mutant advanced
#NSCLC
.
#lcsm
#ELCC25
@myesmo.bsky.social
www.targetedonc.com/view/final-o...
loading . . .
Final OS Results From MARIPOSA Trial in EGFR-Mutant NSCLC
Nicolas Girard, MD, PhD, discusses the final overall survival results from the MARIPOSA trial of amivantamab plus lazertinib in EGFR-mutant advanced non–small cell lung cancer.
https://www.targetedonc.com/view/final-os-results-from-mariposa-trial-in-egfr-mutant-nsclc
about 1 year ago
0
2
0
The
#FDA
approved cabozantinib for adult and pediatric patients aged 12+ with previously treated, unresectable, locally advanced/metastatic, well-differentiated pancreatic neuroendocrine tumors & well-differentiated extra-pancreatic neuroendocrine tumors.
www.targetedonc.com/view/fda-app...
about 1 year ago
0
0
0
Load more
feeds!
log in
